Antineoplastics and immunomodulators 2026-II Cytostatikums content of the active substance amivantamab
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Contract Description
Antineoplastics and immunomodulators 2026-II Cytostatikums content of the active substance amivantamab
Ampoules containing 350 mg of amivantamab, expected annual volume of 220 ampoules (doses); ampoule containing 1,600 mg of amivantamab, estimated annual volume of 12 ampoules (doses); ATC L01FX18
Related Procurement Opportunities
Similar tenders in Pharmaceuticals, Healthcare Equipment and Services, Chemicals